358 related articles for article (PubMed ID: 11714450)
1. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
[TBL] [Abstract][Full Text] [Related]
3. In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs.
Hiramatsu HP; Kikuchi Y; Seto H; Nagata I
Anticancer Drugs; 2000 Aug; 11(7):573-8. PubMed ID: 11036961
[TBL] [Abstract][Full Text] [Related]
4. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
5. Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells.
Wang Z; Xie Y; Wang H
Cancer Biol Ther; 2005 Jul; 4(7):716-9. PubMed ID: 15970709
[TBL] [Abstract][Full Text] [Related]
6. Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells.
Kamazawa S; Kigawa J; Minagawa Y; Itamochi H; Shimada M; Takahashi M; Sato S; Akeshima R; Terakawa N
Oncology; 2000 Nov; 59(4):329-35. PubMed ID: 11096346
[TBL] [Abstract][Full Text] [Related]
7. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin efflux, binding and intracellular pH in the HTB56 human lung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant.
Chau Q; Stewart DJ
Cancer Chemother Pharmacol; 1999; 44(3):193-202. PubMed ID: 10453720
[TBL] [Abstract][Full Text] [Related]
9. [Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum].
Zhang W; Wu FX; Wang Q; Li L
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):286-91. PubMed ID: 22781116
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition of Topo II alpha gene expression and reversing of drug resistance in multi-drug resistant epithelial ovarian cancer cells induced by RNA interference in vitro].
He J; Li L; Tang BJ; Zhang W; Li DR; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):686-90. PubMed ID: 20079182
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine. HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin.
Kudoh K; Kikuchi Y; Hiramatsu H; Hirata J; Yamamoto K; Kita T; Nagata I
Eur J Cancer; 1997 Jan; 33(1):122-8. PubMed ID: 9071911
[TBL] [Abstract][Full Text] [Related]
13. HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
Li Y; Sun J; Gao S; Hu H; Xie P
Gene; 2018 Jul; 663():9-16. PubMed ID: 29660518
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
15. The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
Minagawa Y; Kigawa J; Itamochi H; Terakawa N
Hum Cell; 2001 Sep; 14(3):237-43. PubMed ID: 11774743
[TBL] [Abstract][Full Text] [Related]
16. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.
Katano K; Kondo A; Safaei R; Holzer A; Samimi G; Mishima M; Kuo YM; Rochdi M; Howell SB
Cancer Res; 2002 Nov; 62(22):6559-65. PubMed ID: 12438251
[TBL] [Abstract][Full Text] [Related]
17. An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells.
Chen ZS; Sumizawa T; Furukawa T; Ono K; Tani A; Komatsu M; Akiyama S
Cancer Lett; 1999 Apr; 138(1-2):13-22. PubMed ID: 10378768
[TBL] [Abstract][Full Text] [Related]
18. Human multidrug resistance associated protein 4 confers resistance to camptothecins.
Tian Q; Zhang J; Tan TM; Chan E; Duan W; Chan SY; Boelsterli UA; Ho PC; Yang H; Bian JS; Huang M; Zhu YZ; Xiong W; Li X; Zhou S
Pharm Res; 2005 Nov; 22(11):1837-53. PubMed ID: 16132345
[TBL] [Abstract][Full Text] [Related]
19. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
Andrews PA; Velury S; Mann SC; Howell SB
Cancer Res; 1988 Jan; 48(1):68-73. PubMed ID: 3335000
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]